Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Padmanee Sharma

Showing results (191-200 of 216) with videos related to

Pageof 22
Sort By:
The Lancet. Oncology|January 24, 2018
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trialRodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, et al.
Cancer Cell|May 4, 2020
Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary CarcinomaPavlos Msaouel, Gabriel G Malouf, Xiaoping Su, et al.
The Journal of Experimental Medicine|August 27, 2024
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancerApostolia M Tsimberidou, Farah A Alayli, Kwame Okrah, et al.
Nature|March 9, 2023
Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanomaRodabe N Amaria, Michael Postow, Elizabeth M Burton, et al.
Nature|October 26, 2022
Neoadjuvant relatlimab and nivolumab in resectable melanomaRodabe N Amaria, Michael Postow, Elizabeth M Burton, et al.
Nature Medicine|October 10, 2018
Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Nature Medicine|October 27, 2018
Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Science Translational Medicine|March 3, 2017
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistanceWhijae Roh, Pei-Ling Chen, Alexandre Reuben, et al.
Nature Medicine|October 27, 2018
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Science Translational Medicine|October 8, 2025
Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analysesAlexander L Ling, Jennifer Gantchev, Michael C Prabhu, et al.
Pageof 22

Showing results (191-200 of 216) with videos related to

Sort By:
Pageof 22
The Lancet. Oncology|January 24, 2018
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trialRodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, et al.
Cancer Cell|May 4, 2020
Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary CarcinomaPavlos Msaouel, Gabriel G Malouf, Xiaoping Su, et al.
The Journal of Experimental Medicine|August 27, 2024
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancerApostolia M Tsimberidou, Farah A Alayli, Kwame Okrah, et al.
Nature|March 9, 2023
Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanomaRodabe N Amaria, Michael Postow, Elizabeth M Burton, et al.
Nature|October 26, 2022
Neoadjuvant relatlimab and nivolumab in resectable melanomaRodabe N Amaria, Michael Postow, Elizabeth M Burton, et al.
Nature Medicine|October 10, 2018
Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Nature Medicine|October 27, 2018
Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Science Translational Medicine|March 3, 2017
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistanceWhijae Roh, Pei-Ling Chen, Alexandre Reuben, et al.
Nature Medicine|October 27, 2018
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Science Translational Medicine|October 8, 2025
Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analysesAlexander L Ling, Jennifer Gantchev, Michael C Prabhu, et al.
Pageof 22